News

Nanoprobes are optical probes that light up when attached to tumors. Researchers have developed a new type of nanoprobe, designed to detect cancer more accurately.

An early clinical trial in patients with glioblastoma showed an experimental spherical nucleic acid (SNA) drug, developed by Northwestern University scientists, was able to penetrate the blood–brain barrier and trigger the destruction of tumor cells.

A new study shows that whole genome sequencing is often more accurate than conventional genetic tests and could help determine the treatment for blood cancers such as acute myeloid leukemia and myelodysplastic syndrome.

A new study has shown that telomeres respond to external signals that induce cell proliferation, by blocking these signals it is possible to disrupt the process cancer cells exploit to become immortal.

Polygenic risk scores represent a new approach for assessing a person's inherited risk for certain diseases such as Type 2 diabetes or coronary heart disease. A set of new guidelines for reporting polygenic risk scores in a consistent way, and the launch of an open database for these scores could make the data more useful in clinical care.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer. Now, researchers have designed a new method to detect circulating tumor cells (CTCs), a telltale sign of metastases, in patients with NSCLC.

At present, drug response in cancer patients cannot be predicted. A research team has developed a new strategy for the generation of prostate cancer organoids that can contribute to the assessment of therapy response.

An international team of scientists has discovered that extracts of a weedy grass called Andropogon virginicus appear to be effective against several human diseases, including diabetes and cancer.

The analysis of immune cells infiltrating cerebrospinal fluid enables the characterization of the tumor microenvironment in brain metastases. Findings confirm that these cells could act as novel and non-invasive biomarkers to predict patient responsiveness to immune-based therapies.

A team of researchers from Martin Luther University Halle-Wittenberg and the University of Greifswald has developed a new inhibitor of multi-drug resistant protein 4 (MRP4). When the inhibitor was tested on drug-resistant cancer cell lines, the cancer cells began to respond to chemotherapy.